Literature DB >> 25747766

Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.

Susan Hofman1, Mathieu S Bolhuis, Remco A Koster, Onno W Akkerman, Sander van Assen, Christophe Stove, Jan-Willem C Alffenaar.   

Abstract

Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment. We subsequently examined potential use of dried blood spots as sample procedure for TDM. TDM was found to be an important component of clinical care for many (but not all) pulmonary infections. For gentamicin, linezolid, voriconazole and posaconazole dried blood spot methods and their use in TDM were already evident in literature. For glycopeptides, β-lactam antibiotics and fluoroquinolones it was determined that development of a dried blood spot (DBS) method could be useful. This review identifies specific antibiotics for which development of DBS methods could support the optimization of treatment of pulmonary infections.

Entities:  

Mesh:

Year:  2015        PMID: 25747766     DOI: 10.4155/bio.14.318

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  3 in total

1.  Metabolomics technology and bioinformatics for precision medicine.

Authors:  Rajeev K Azad; Vladimir Shulaev
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

2.  A feasibility study of metabolic phenotyping of dried blood spot specimens in rural Chinese women exposed to household air pollution.

Authors:  Ruey Leng Loo; Qinwei Lu; Ellison M Carter; Si Liu; Sierra Clark; Yulan Wang; Jill Baumgartner; Huiru Tang; Queenie Chan
Journal:  J Expo Sci Environ Epidemiol       Date:  2020-07-24       Impact factor: 5.563

3.  Clinical standards for drug-susceptible pulmonary TB.

Authors:  O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-07-01       Impact factor: 3.427

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.